You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

175 Results
Regimen
Cancer Type:
Gynecologic, 
Cervix, 
Endometrial, 
Ovary, 
Vulva
Intent: Adjuvant, Palliative
Nov 2024
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative
May 2020
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Nov 2024
Regimen
Regimen
Intent: Palliative
May 2020
Regimen
Intent: Palliative
Nov 2024
Regimen
Intent: Palliative
Nov 2024
Regimen
Intent: Palliative
Nov 2024
Regimen
Intent: Palliative
Aug 2020
Regimen
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
ODB - General Benefit
  • cyclophosphamide - oral tablets
New Drug Funding Program
  • Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
  • Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
New Drug Funding Program
  • Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
  • Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
Aug 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Palliative
Oct 2020

Pages